期刊文献+

药物洗脱支架与金属支架置入后再狭窄及其生物相容性比较 被引量:4

Comparison of restenosis and biocompatibility between drug eluting stent and metal stent following implantation
下载PDF
导出
摘要 目的:比较并总结金属裸支架与药物洗脱支架的生物相容性及支架置入后的冠状动脉再狭窄,展望生物可降解支架的临床应用。方法:以药物洗脱支架,金属裸支架,生物相容性,再狭窄为检索词,检索中国期刊全文数据库(1999-01/2009-06),以drugelutingstent,baremetalstent,biocompatibility,restenosis为检索词,检索PubMed数据库(1999-01/2009-06),文献检索语种限制为中文和英文。以再狭窄率,支架的生物相容性及炎症因子的表达为评价指标。纳入药物洗脱支架与金属支架置入后血管再狭窄的临床研究;排除动物实验。结果:计算机初检得到523篇文献,根据纳入排除标准,对金属裸支架与药物洗脱支架置入后血管再狭窄的临床研究进行分析。经皮冠状动脉支架置入已成为治疗冠状动脉粥样硬化性心脏病最常用的治疗方法,其主要包括球囊扩张、普通金属裸支架置入、药物洗脱支架置入。用普通金属裸支架取代球囊扩张,使支架内再狭窄由50%下降到20%~30%;药物洗脱支架改善了冠状动脉介入治疗的愈后,但同时也带来了许多新问题。大多数药物洗脱支架由药物、药物载体、支架平台3部分组成,其中金属支架和聚合物不能被人体吸收。金属置入物和药物载体长期存留于血管中,影响内皮化、引起局部的慢性炎症反应和后期的血栓形成。结论:药物洗脱支架在防止支架内再狭窄及再次血运重建明显优于普通金属裸支架。生物可降解支架的临床应用,在一定程度上减少了药物载体对血管内皮的影响。 OBJECTIVE: To compare the biocompatibility, as well as restenosis following drug eluting stent and metal stent implantation, in addition, to prospect the clinical application of biodegradable stent. METHODS: Chinese Journal Full-Text Database and Pubmed were retrieved with key words of drug eluting stent, bare metal stent, biocompatibility, and restenosis, from January 1999 to June 2009. The language was restricted within Chinese and English Simultaneously, restenosis, biocompatibility and inflammatory factor expression was acted as evaluation index. Accordingly, clinical research concerning restenosis following stent implantation was included. The animal experiment was excluded. RESULTS: A total of 523 literatures were obtained by initial search with computer. According to inclusion criteria, the related papers were analyzed. Percutaneous transluminal coronary stenting is the major treatment for coronary atherosclerotic heart disease, which comprises balloon dilation, bare metal stenting, and drug eluting stent implantation. When balloon dilation was replaced by bare metal stenting, the restenosis rate was reduced from 50% to 20%-30%. The drug eluting stent composed of drug, drug carrier, and scaffold, which ameliorate healing following coronary intervention. However, the non-degradable stent remained in the blood vessel for a long time, which effected endothelialization and resulted in chronic inflammatory reaction, as well as thrombosis following implantation. CONCLUSION: The drug eluting stent exhibits superiority in preventing restenosis and repeat revascularization than bare metal stent. Furthermore, the application of biodegradable stent reduces the effect of drug carrier on blood vessel endothelium.
作者 杜长春
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2009年第39期7735-7738,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献30

  • 1高润霖,陈纪林,杨跃进,乔树宾,徐波,姚民,秦学文,姚康宝,李贤,武阳丰.冠状动脉内支架植入术后再狭窄的危险因素和预测[J].中华心血管病杂志,2000,28(6):426-429. 被引量:25
  • 2Mach F.Toward new therapeutic strategies against neointimal formation in restenosis.Arterioscler Thromb Vasc Biol.2000;20(7):1699-1700.
  • 3Hamasaki N,Nosaka H,Kimura T,et al.Initial experience with the Cordis stent:analysis of serial angiographic follow-up.Cathet Cardiovasc Diagn.1997;42(2)166-172.
  • 4Ribichini F,Wijns W,Ferrero V,et al.Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting.Am J Cardiol.2003;91(2):154-158.
  • 5Palmaz JC,Bailey S,Marton D,et al.Influence of stent design and material composition on procedure outcome.J Vasc Surg.2002:36(5):1031-1039.
  • 6高东升.冠状动脉内照射对再狭窄的防治作用及其存在的问题[J].心脏杂志,2002,14(5):443-445. 被引量:7
  • 7Orford JL,Fasseas只Denktas AE,et al.Safety and efficacy of cutting balloon angioplasty:the Mayo Clinic experience.J Invasive Cardiol.2002;14(12):720-724.
  • 8Radke PW,Blindt R,Haager PK,et al.Rotational atherectomy for the treatment of in-stent restenosis.Minerva Cardioangiol.2002;50(5):555-563.
  • 9Garza L,Aude YW,Saucedo JF.Can we prevent in-stent restenosis?Curr Opin Cardiol.2002;17(5):518-525.
  • 10Regar E,Serruys PW,Bode C,et al.Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent(RAVEL):sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.Circulation.2002;106(15):1949-1956.

二级参考文献54

  • 1肖越勇,张金山,崔福斋,孟波.生物可降解性血管内支架的制备及其性能研究[J].中华放射学杂志,2003,37(11):1036-1042. 被引量:27
  • 2韩雅玲,刘海伟,荆全民,王守力,王祖禄,王冬梅,马颖艳,栾波,王耿.药物洗脱支架治疗冠状动脉小血管病变的疗效分析[J].中国实用内科杂志:临床前沿版,2006,26(7):1062-1065. 被引量:3
  • 3Fukuda D,Shimada K,Tanaka A,et al.Circulating monocytes and in-stent neointima after coronary stent implantation.J Am Coll Cardiol ,2004,43:18-23.
  • 4Wilensky R L,March K L,Gradus-Pizlo I,et al.Vascular injury,repair,and restenosis after percu taneous transluminal angioplasty in the atherosclerotic rabbit.Circulation,1995,92:2995-3005.
  • 5Kornowski R, Hong M K, Tio F O, et al.In-stent restenosis:Contributions of inflammatory responses and arterial injury to neointimal hyperplasia.J Am Coll Cardiol,1998,31:224-230.
  • 6Shi Y,O′Brien J E,Fard A,et al.Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries.Circulation,1996,94:1655-1664.
  • 7Regar E,Serruys P W,Bode C,et al.Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx Velocity balloon-expandable stent(RAVEL):Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.Circulation,2002,106:1949-1956.
  • 8Holmes D R Jr,Leon M B,Moses J W,et al.One year follow-up of the SIRIUS study:A randomized study with the sirolimus-eluting Bx VelocityTM in the treatment of patients with de novo native coronary artery lesions.J Am Coll Cardiol,2003,41(Suppl A):32A.
  • 9Stone G W, Ellis S G,Cox D A,et al.A polymer-based,paclitaxel-eluting stent in patients with coronary artery disease.N Engl J Med ,2004,350:221-231.
  • 10Kataoka T, Grube E, Honda Y,et al.7-hexanoyltaxol-eluting stent for prevention of neointimal growth:An intravascular ultrasound analysis from the study to compare restenosis rate between quest and quads-QP2(SCORE).Circulation,2002,106:1788-1793.

共引文献68

同被引文献15

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部